Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

Immunovant (IMVT) announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two ...

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours that have been swirling ...

However, Roche has been particularly active in immunology in recent years, cutting deals to acquire gut disease drug developer Telavant as well as autoimmune and cancer cell therapy maker Poseida ...

Immunovant, Inc. (IMVT) announced on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, ...

Renee Barnett stepped down from her position as Immunovant CFO; she is succeeded by Tiago Girao, formerly Telavant CFO. Immunovant has announced these changes in conjunction with a broader ...

Renee Barnett stepped down from her position as Immunovant CFO; she is succeeded by Tiago Girao, formerly Telavant CFO. Immunovant has announced these changes in conjunction with a broader ...

A recent example and success story of such a model was the $7.1 billion deal between Roche and Telavant for a drug candidate developed through a joint venture between the latter company and Pfizer.